Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lanabecestat in Hepatic Impairment
NCT03499041Phase 1Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) at 240 hours and Maximum Observed Drug Concentration at 240 hours. Planned start Jun 2018; status: withdrawn.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03499041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499041.